• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of pharmaceutical sciences >Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations.
【24h】

Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations.

机译：使用基于脱乙酰壳多糖的粉末制剂在绵羊体内鼻内递送重组人生长激素（生长激素）。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The effectiveness of chitosan in promoting the intranasal bioavailability of recombinant human growth hormone (hGH) has been evaluated. hGH was formulated with chitosan to produce a powder blend (Formulation A) and granules (Formulation B) for intranasal administration. The in vivo pharmacokinetic performance of the formulations was evaluated in a group of six sheep in a randomised crossover study. A subcutaneous injection of hGH solution was administered as a control. The intranasal and subcutaneous doses of hGH were 0.3 and 0.03 mg/kg, respectively. The intranasal formulations appeared to be well tolerated. Mean bioavailabilities of hGH from Formulations A and B were 14 and 15%, respectively relative to subcutaneous injection. It is concluded that chitosan-based intranasal powder formulations may provide a practical means for non-injectable delivery of hGH and, potentially, other therapeutic protein molecules.
机译：已经评估了壳聚糖在促进重组人生长激素（hGH）鼻内生物利用度方面的有效性。将hGH与壳聚糖一起配制以产生用于鼻内施用的粉末共混物（制剂A）和颗粒（制剂B）。在随机交叉研究中，在六只绵羊的一组中评估了制剂的体内药代动力学性能。皮下注射hGH溶液作为对照。鼻内和皮下注射hGH的剂量分别为0.3和0.03 mg / kg。鼻内制剂似乎耐受良好。相对于皮下注射，来自制剂A和B的hGH的平均生物利用度分别为14％和15％。结论是，基于壳聚糖的鼻内粉剂可为hGH和潜在的其他治疗性蛋白分子的不可注射递送提供实用的手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号